128 related articles for article (PubMed ID: 17334744)
1. [Depression of respiration via toxic effects on the central nervous system following use of topical brimonidine in an infant with congenital glaucoma].
Heimann K; Peschgens T; Merz U; Hoernchen H; Wenzl T
Ophthalmologe; 2007 Jun; 104(6):505-7. PubMed ID: 17334744
[TBL] [Abstract][Full Text] [Related]
2. Apparent central nervous system depression in infants after the use of topical brimonidine.
Carlsen JO; Zabriskie NA; Kwon YH; Barbe ME; Scott WE
Am J Ophthalmol; 1999 Aug; 128(2):255-6. PubMed ID: 10458196
[TBL] [Abstract][Full Text] [Related]
3. Can ophthalmic drops cause central nervous system depression and cardiogenic shock in infants?
Kiryazov K; Stefova M; Iotova V
Pediatr Emerg Care; 2013 Nov; 29(11):1207-9. PubMed ID: 24196091
[TBL] [Abstract][Full Text] [Related]
4. Brimonidine Toxicity Secondary to Topical Use for an Ulcerated Hemangioma.
Gill K; Bayart C; Desai R; Golden A; Raimer P; Tamburro J
Pediatr Dermatol; 2016 Jul; 33(4):e232-4. PubMed ID: 27282306
[TBL] [Abstract][Full Text] [Related]
5. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.
Mungan NK; Wilson TW; Nischal KK; Koren G; Levin AV
J AAPOS; 2003 Feb; 7(1):69-70. PubMed ID: 12690374
[TBL] [Abstract][Full Text] [Related]
6. Is brimonidine ophthalmic a safe therapy for infants?
Daubert GP
J Clin Pharm Ther; 2006 Jun; 31(3):289-92. PubMed ID: 16789995
[TBL] [Abstract][Full Text] [Related]
7. Brimonidine 0.2% to prevent post laser IOP elevation.
Kasahara N
Ophthalmology; 2002 May; 109(5):828-9; author reply 829. PubMed ID: 11986075
[No Abstract] [Full Text] [Related]
8. A review of neuropsychiatric adverse events from topical ophthalmic brimonidine.
Cimolai N
Hum Exp Toxicol; 2020 Oct; 39(10):1279-1290. PubMed ID: 32347114
[TBL] [Abstract][Full Text] [Related]
9. Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children.
Bowman RJ; Cope J; Nischal KK
Eye (Lond); 2004 Jan; 18(1):24-6. PubMed ID: 14707960
[TBL] [Abstract][Full Text] [Related]
10. Apneic spells associated with timolol therapy in a neonate.
Olson RJ; Bromberg BB; Zimmerman TJ
Am J Ophthalmol; 1979 Jul; 88(1):120-2. PubMed ID: 464000
[TBL] [Abstract][Full Text] [Related]
11. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of the effects of brimonidine and dorzolamide on ocular blood flow velocity in patients with newly diagnosed primary open-angle glaucoma.
Simsek T; Yanik B; Conkbayir I; Zilelioglu O
J Ocul Pharmacol Ther; 2006 Apr; 22(2):79-85. PubMed ID: 16722793
[TBL] [Abstract][Full Text] [Related]
13. Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients.
Nguyen QH; Earl M
J Ocul Pharmacol Ther; 2009 Dec; 25(6):541-4. PubMed ID: 20028261
[TBL] [Abstract][Full Text] [Related]
14. [Phase III clinical trial of brimonidine in patients with primary open-angle glaucoma and ocular hypertension--comparison of the effects of brimonidine monotherapy versus timolol monotherapy, or combination brimonidine/prostaglandins therapy versus combination placebo/prostaglandins therapy].
Araie M; Yamazaki Y; Sugiyama K; Kuwayama Y; Tanihara H
Nippon Ganka Gakkai Zasshi; 2012 Oct; 116(10):955-66. PubMed ID: 23285843
[TBL] [Abstract][Full Text] [Related]
15. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: a prospective, unmasked study.
Tsai JC; Chang HW
J Ocul Pharmacol Ther; 2005 Dec; 21(6):475-82. PubMed ID: 16386089
[TBL] [Abstract][Full Text] [Related]
17. Cardiorespiratory depression and hyperglycemia after unintentional ingestion of brimonidine in a neonate.
Vanhaesebrouck S; Cossey V; Cosaert K; Allegaert K; Naulaers G
Eur J Ophthalmol; 2009; 19(4):694-5. PubMed ID: 19551691
[TBL] [Abstract][Full Text] [Related]
18. Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine.
Kim SN; Ko SA; Park CG; Lee SH; Huh BK; Park YH; Kim YK; Ha A; Park KH; Choy YB
Mol Pharm; 2018 Aug; 15(8):3143-3152. PubMed ID: 30020792
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
thoe Schwartzenberg GW; Buys YM
Ophthalmology; 1999 Aug; 106(8):1616-20. PubMed ID: 10442912
[TBL] [Abstract][Full Text] [Related]
20. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
